---
title: "MediWound Q2 FY26 net loss narrows to USD 7.4 million; revenue drops to USD 3.1 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295786929.md"
description: "MediWound reported Q2 FY26 results with revenue dropping 45.85% to USD 3.1 million and operating loss widening to USD 9.5 million. However, the net loss narrowed to USD 7.4 million due to non-cash financial income. R&D expenses increased to USD 5.9 million for the EscharEx Phase III trial. Cash reserves fell to USD 36 million. The company reaffirmed its full-year 2026 revenue guidance of USD 24-26 million."
datetime: "2026-08-13T11:06:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295786929.md)
  - [en](https://longbridge.com/en/news/295786929.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295786929.md)
---

# MediWound Q2 FY26 net loss narrows to USD 7.4 million; revenue drops to USD 3.1 million

-   MediWound posted Q2 revenue of USD 3.1 million, down 45.85% year over year; operating loss widened to USD 9.5 million. \* Net loss narrowed to USD 7.4 million, or USD 0.57 per share, versus USD 13.3 million, on non-cash financial income. \* R&D expense rose to USD 5.9 million from USD 3.5 million, reflecting higher investment in the EscharEx Phase III VALUE trial. \* Cash, cash equivalents and deposits totaled USD 36 million at June 30, down from USD 54 million at year-end 2025. \* Full-year 2026 revenue guidance of USD 24-26 million was reaffirmed, with MSA revenue under Vericel’s BARDA contract expected in H2 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediWound Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608130700PRIMZONEFULLFEED9808849) on August 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [MDWD.US](https://longbridge.com/en/quote/MDWD.US.md)
- [VCEL.US](https://longbridge.com/en/quote/VCEL.US.md)

## Related News & Research

- [MediWound Ltd. (NASDAQ:MDWD) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates](https://longbridge.com/en/news/296027865.md)
- [MediWound posts investor presentation on enzymatic burn and chronic-wound therapies NexoBrid, EscharEx](https://longbridge.com/en/news/295787062.md)
- [MDWD: Validated enzymatic therapies drive strong growth, targeting $1B+ peak sales in chronic wounds](https://longbridge.com/en/news/295787113.md)
- [MediWound (NASDAQ:MDWD) Issues Earnings Results](https://longbridge.com/en/news/295866831.md)
- [MDWD: Q2 revenue fell, but guidance held as EscharEx and NexoBrid programs advanced and U.S. sales grew](https://longbridge.com/en/news/295796876.md)